KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Profit After Tax (2023 - 2025)

Biocryst Pharmaceuticals' Profit After Tax history spans 9 years, with the latest figure at $245.8 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 1017.5% year-over-year to $245.8 million; the TTM value through Dec 2025 reached $263.9 million, up 396.87%, while the annual FY2025 figure was $263.9 million, 396.87% up from the prior year.
  • Profit After Tax reached $245.8 million in Q4 2025 per BCRX's latest filing, up from $12.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $245.8 million in Q4 2025 to a low of -$201.7 million in Q4 2023.
  • Average Profit After Tax over 3 years is -$3.0 million, with a median of -$12.7 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: surged 86.71% in 2024, then soared 1017.5% in 2025.
  • A 3-year view of Profit After Tax shows it stood at -$201.7 million in 2023, then soared by 86.71% to -$26.8 million in 2024, then skyrocketed by 1017.5% to $245.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Profit After Tax are $245.8 million (Q4 2025), $12.9 million (Q3 2025), and $5.1 million (Q2 2025).